Surrogate end points in clinical trials: are we being misled? - PubMed (original) (raw)

Review

Surrogate end points in clinical trials: are we being misled?

T R Fleming et al. Ann Intern Med. 1996.

No abstract available

PubMed Disclaimer

Comment in

• POEMs: patient-oriented evidence that matters.
  Shaughnessy AF, Slawson DC. Shaughnessy AF, et al. Ann Intern Med. 1997 Apr 15;126(8):667. doi: 10.7326/0003-4819-126-8-199704150-00032. Ann Intern Med. 1997. PMID: 9103150 No abstract available.

Similar articles

• "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
  Penel N, Clisant S, Lefebvre JL, Adenis A. Penel N, et al. J Clin Oncol. 2009 Sep 10;27(26):e105. doi: 10.1200/JCO.2009.24.1810. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667257 No abstract available.
• Interim analyses in clinical trials: why do we plan them?
  Fossâ SD, Skovlund E. Fossâ SD, et al. J Clin Oncol. 2000 Dec 15;18(24):4007-8. doi: 10.1200/JCO.2000.18.24.4007. J Clin Oncol. 2000. PMID: 11118460 No abstract available.
• Randomized phase II trials: misleading and unreliable.
  Stewart DJ. Stewart DJ. J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855829 No abstract available.
• Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?
  Marty FM, Boeckh M. Marty FM, et al. Curr Opin Virol. 2011 Dec;1(6):555-62. doi: 10.1016/j.coviro.2011.10.011. Epub 2011 Nov 4. Curr Opin Virol. 2011. PMID: 22440913 Review.
• Novel endpoints and design of early clinical trials.
  Parulekar WR, Eisenhauer EA. Parulekar WR, et al. Ann Oncol. 2002;13 Suppl 4:139-43. doi: 10.1093/annonc/mdf651. Ann Oncol. 2002. PMID: 12401680 Review. No abstract available.

Cited by

• Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation framework.
  Cho D, Lord SJ, Ward R, IJzerman M, Mitchell A, Thomas DM, Cheyne S, Martin A, Morton RL, Simes J, Lee CK. Cho D, et al. Ther Adv Med Oncol. 2024 Sep 2;16:17588359241273062. doi: 10.1177/17588359241273062. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39229469 Free PMC article.
• Precursors in cancer epidemiology: aligning definition and function.
  Wacholder S. Wacholder S. Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):521-7. doi: 10.1158/1055-9965.EPI-13-0084. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23549395 Free PMC article.
• Biomarkers of Cognitive Training Effects in Aging.
  Belleville S, Bherer L. Belleville S, et al. Curr Transl Geriatr Exp Gerontol Rep. 2012 Apr 19;1(2):104-110. doi: 10.1007/s13670-012-0014-5. Print 2012 Jun. Curr Transl Geriatr Exp Gerontol Rep. 2012. PMID: 23864998 Free PMC article.
• Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.
  Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Ciani O, et al. Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.81. Epub 2016 Jun 3. Nat Rev Drug Discov. 2016. PMID: 27256477 No abstract available.
• How to estimate fat mass in overweight and obese subjects.
  Donini LM, Poggiogalle E, Del Balzo V, Lubrano C, Faliva M, Opizzi A, Perna S, Pinto A, Rondanelli M. Donini LM, et al. Int J Endocrinol. 2013;2013:285680. doi: 10.1155/2013/285680. Epub 2013 Apr 10. Int J Endocrinol. 2013. PMID: 23662101 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database